Derma Sciences to Present at the Noble Financial Equity Conference on June 8

Jun 03, 2010, 14:33 ET from Derma Sciences, Inc.

PRINCETON, N.J., June 3 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that Edward J. Quilty, Chairman and CEO, will make a presentation regarding the business strategy and financial outlook of the Company at the Noble Financial Sixth Annual Equity Conference at 12:30pm EDT on June 8, 2010, at the Hard Rock Hotel in Hollywood, Florida.

The presentation will be webcast LIVE featuring high-definition, streaming video and PowerPoint slides.  Access is available by logging on to It is recommended that interested parties register at least 10 minutes prior to the start of the presentation to ensure timely access. You will need the SilverLight viewer (a free download from presentation link) to participate.

About Derma Sciences, Inc.

Derma Sciences is a global medical device and pharmaceutical company focused on wound care.   Its key product, MEDIHONEY®, is the leading brand of honey-based dressings for the management of wounds and burns.  The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale randomized controlled trial on leg ulcers.  Other key novel products introduced into the $14 billion global wound care market include XTRASORB™ for better management of wound exudates, and BIOGUARD™ for infection prevention.  Derma also has in development DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction.  DSC127, an angiotensin analog, has shown positive healing results in multiple pre-clinical animal models.  One possible mode of action of the drug is the up-regulation of mesenchymal stem cells at the wound site.  Derma expects to announce the key efficacy endpoint results from this study by the end of 2010.

For more information about Derma Sciences, Inc., visit

Forward-Looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the Securities and Exchange Commission.


Derma Sciences, Inc.

John Yetter

Vice President and CFO

(609) 514-4744

The Investor Relations Group


Jason Strominger (Investor Relations)

Janet Vasquez (Media Relations)

Enrique Briz (Media Relations)

SOURCE Derma Sciences, Inc.